NasdaqGS - Nasdaq Real Time Price • USD
Apellis Pharmaceuticals, Inc. (APLS)
As of 10:12 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 14 | 13 | 13 |
| Avg. Estimate | -0.31 | -0.13 | -1 | 1.25 |
| Low Estimate | -0.42 | -0.34 | -1.5 | 0.14 |
| High Estimate | -0.12 | 0.26 | 0.2 | 4.09 |
| Year Ago EPS | -1.02 | -1.17 | -4.45 | -1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 15 | 14 |
| Avg. Estimate | 193.61M | 216.56M | 820.88M | 1.21B |
| Low Estimate | 180.27M | 195.36M | 765.9M | 947.13M |
| High Estimate | 230.15M | 262.77M | 959.2M | 1.67B |
| Year Ago Sales | 70.25M | 110.4M | 396.59M | 820.88M |
| Sales Growth (year/est) | 175.60% | 96.20% | 107.00% | 47.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.32 | -0.85 | -0.69 | -0.47 |
| EPS Actual | -1.02 | -1.17 | -0.73 | -0.54 |
| Difference | 0.3 | -0.32 | -0.04 | -0.07 |
| Surprise % | 22.70% | -37.60% | -5.80% | -14.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.13 | -1 | 1.25 |
| 7 Days Ago | -0.33 | -0.14 | -0.96 | 1.29 |
| 30 Days Ago | -0.37 | -0.24 | -1.23 | 1.2 |
| 60 Days Ago | -0.37 | -0.24 | -1.2 | 1.2 |
| 90 Days Ago | -0.35 | -0.23 | -1.01 | 1.56 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 10 | 10 | 11 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 2 |
Growth Estimates
| CURRENCY IN USD | APLS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 69.60% | -- | -- | 8.00% |
| Next Qtr. | 88.90% | -- | -- | 12.40% |
| Current Year | 77.50% | -- | -- | 5.60% |
| Next Year | 225.00% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 33.30% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 5/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Maintains | UBS: Buy to Buy | 5/8/2024 |
| Reiterates | Needham: Buy to Buy | 5/8/2024 |
| Maintains | Mizuho: Neutral to Neutral | 4/29/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/26/2024 |
Related Tickers
CYTK Cytokinetics, Incorporated
59.57
+0.07%
BBIO BridgeBio Pharma, Inc.
29.75
-1.13%
ASND Ascendis Pharma A/S
121.95
+0.69%
MDGL Madrigal Pharmaceuticals, Inc.
224.83
+2.17%
IONS Ionis Pharmaceuticals, Inc.
37.21
-0.27%
IOVA Iovance Biotherapeutics, Inc.
10.29
+0.49%
ALNY Alnylam Pharmaceuticals, Inc.
147.91
-1.00%
LEGN Legend Biotech Corporation
45.30
+0.31%
SRPT Sarepta Therapeutics, Inc.
130.89
-0.37%
KYMR Kymera Therapeutics, Inc.
36.07
+3.20%